SOFTATHOME
26.9.2018 09:02:12 CEST | Business Wire | Press release
SoftAtHome, the software company dedicated to the digital home, and V3D, a leading independent software vendor expert on Telecom data analytics for carrier network operators, announced today the signing of an acquisition agreement.
With SoftAtHome acquiring V3D, the company will be able to deliver a full range of solutions around “analytics for Quality of Experience” for its fixed and mobile operator clients, by relying on the millions of data points collected by V3D.
Thanks to both companies’ expertise, skills and solutions, Carrier Network Operators will benefit from a global value proposition on improving Customer Experience on their fixed and mobile networks.
David VIRET-LANGE, Chief Executive Officer of SoftAtHome, commented: “In an increasingly digital world, consumers expect seamless connectivity with their mobile and tablets wherever they are. Quality of Experience will be naturally measured by the same solutions. The V3D solution portfolio and expertise on mobile and fixed network and the skills of SoftAtHome on Wi-Fi and networking will allow our companies to provide the best-in-class Data Analytics and monitoring tools that will help operators deliver an unmatched Quality of Experience for their customers.”
Philippe VIAL-GRELIER, Co-Founder and Managing Director of V3D, added: “We are pleased to join SoftAtHome and combine our skills to facilitate end-to-end access to the entire Customer Experience value chain for carrier network operators. This merger is part of our desire to strengthen our position in the Telecom data analytics for both fixed and mobile markets.”
About SoftAtHome
SoftAtHome creates software for operators
to deploy services with the best user experience for connectivity, pay
TV, Home Networking and Smart Home products. SoftAtHome products are
deployed with major operators in over 20 million homes over 18
countries. The company based in France and Belgium is still growing with
over 250 employees mainly in software development. We are regularly
opening new offices to support our customers. Offices are already in
half a dozen European capitals as well as in Dubai, Singapore and
Toronto. www.softathome.com
About V3D
Specialized in mobile and fixed network
technologies, V3D Solutions enable carrier network operators to monitor
the true network Quality of Experience (QoE) straight from the
subscribers’ perspective. This approach to traditional measurement
methods of network performance offers technical and business benefits to
various departments of an operator, from CEM & Marketing to Network
Operations or Customer Care.
V3D product portfolio focuses on
customer experience and carrier network service performance. The EQual
One solution is based on a combination of Device Quality Agents (DQA)
deployed on commercial devices and a powerful server interacting
over-the-air with the DQAs and potentially integrated with existing
systems. V3D headquarters are based in Lyon, France. For more
information, visit: www.v3d.fr
View source version on businesswire.com: https://www.businesswire.com/news/home/20180926005082/en/
Contact:
Media SoftAtHome Marta TWARDOWSKA, M: +31 621-184-585 e: press@softathome.com T: @SoftAtHome www.softathome.com or V3D Hélène VALLEE, + 33 481 761 370 hvallee@v3d.fr press@v3d.fr www.v3d.fr
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press release
Intranasal pertussis vaccine candidate BPZE1 demonstrates robust nasal mucosal and systemic immune responses with a favorable safety profile in children ages 6 through 17 yearsFirst pediatric clinical trial builds on 5 prior adult BPZE1 clinical studiesDemonstrates safety and immunogenicity of BPZE1 in acellular pertussis vaccine primed individualsNo interference observed when BPZE1 co-administered with diphtheria and tetanus antigens ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The stu
NIQ Brings New AI and Automation Capabilities to Retail Space Planning and Merchandising2.10.2026 12:45:00 CEST | Press release
New AI and automation capabilities help retailers close execution gaps and scale merchandising decisions across every store. NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced new AI and automation capabilities for NIQ Spaceman®, its retail space planning and merchandising platform trusted by more than 600 retailers across 65+ countries. The enhancements help retailers create store-specific planograms up to 50 times faster, identify execution and compliance gaps, and scale merchandising decisions across their store networks through expanded cloud-based access. "Retailers are under increasing pressure to localize assortments, execute consistently across stores, and respond more quickly to changing shopper behavior," said Natalie Williams, SVP, Product at NIQ. "These enhancements help simplify that process by embedding agentic AI directly into merchandising workflows and automating traditionally manual planning tasks. That means teams can spend less time buil
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2.10.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior leader were granted on September 30, 2026 and consisted of options to purchase an aggregate of 121,800 shares and restricted share units covering an aggregate of 58,000 shares. The options have an exercise price per share equal to $12.44. The equity awards to the ten newly hired non-executive employees were granted on October 1, 2026 and consisted of options to purchase an aggregate of 97,100 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 46,200 shares. These options have an exercise price per share equal to $11.95, the closing price of the Company’s American De
Global Health Leaders to Convene at Abu Dhabi Future Health Summit 20262.10.2026 12:24:00 CEST | Press release
Abu Dhabi Future Health Summit will convene leaders across healthcare, science, technology, policy, and investment from 20-22October at ADNEC Centre Abu DhabiUnder the 2026 theme ‘To Sense is to Predict’, the Future Health Summit will examine how greater health insight can enable earlier intervention and better outcomesAstraZeneca CEO Sir Pascal Soriot, Isomorphic Labs President Mr. Max Jaderberg, Amref Health Africa Group CEO Dr. Githinji Gitahi, and Health Ministers from Kosovo, Montenegro, Serbia and Colombia are among more than 130 Forum speakers, with participation expected from 100 countries Global leaders across healthcare, science, technology, policy, and investment will convene at the Abu Dhabi Future Health Summit from 20 to 22 October 2026 to examine how health systems can better anticipate risk and enable earlier intervention as advances in AI, genomics, diagnostics, and health data create new possibilities for understanding health risks earlier. This press release features
Venture Global and ConocoPhillips Announce 20-Year LNG Sales and Purchase Agreement1.10.2026 22:30:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and ConocoPhillips (NYSE: COP) announced a new, long-term Sales and Purchase Agreement (SPA) for liquefied natural gas (LNG). Under the SPA, ConocoPhillips will buy 1.0 million tonnes per annum (MTPA) of LNG from Venture Global for 20 years, starting in 2030. "Venture Global is proud to welcome ConocoPhillips, one of the world's leading energy companies, as a long-term partner," said Venture Global CEO Mike Sabel. "This agreement reflects continued market confidence in our proven ability to deliver reliable, low-cost U.S. LNG quickly and at scale. We look forward to supporting ConocoPhillips' growing global LNG portfolio for decades to come." About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom